

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 9/00, 9/14, 9/50, 9/51, 47/24, 47/06</b>		<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/38493</b>
			<b>(43) International Publication Date:</b> 5 August 1999 (05.08.99)
<b>(21) International Application Number:</b> PCT/US98/27922 <b>(22) International Filing Date:</b> 30 December 1998 (30.12.98) <b>(30) Priority Data:</b> 09/016,265 30 January 1998 (30.01.98) US <b>(71) Applicant (for all designated States except US):</b> RTP PHARMA INC. [CA/CA]; 810, chemin du Golf, 11e des Soeurs, Quebec H3E 1A8 (CA). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> MOUSSA, Iskandar [CA/CA]; Apartment #108, 4850 Cote des Neiges, Montreal, Quebec H3V 1G5 (CA). PARIKH, Indu [CA/US]; 120 Ferland, 11e des Soeurs, Verdun, Quebec H3E 1L1 (CA). <b>(74) Agent:</b> CRAWFORD, Arthur, R.; Nixon & Vanderhye P.C., 8th floor, 1100 North Glebe Road, Arlington, VA 22201-4714 (US).			<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> MICROPARTICLE INHALATION FORMULATIONS			
<b>(57) Abstract</b>  Aerosol formulations containing stabilized particles of drug microparticles with a mean size range of 0.1 to 10 microns coated with a membrane-forming amphiphatic lipid and dispersed in 1,1,1,2-tetrafluoroethane (HFA 134a) of 1,1,1,2,3,3,3-heptafluoropropane (HFA 227) propellant.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## **MICROPARTICLE INHALATION FORMULATIONS**

This invention relates to aerosol formulations of drug microparticles coated with a lipid membrane and suspended in a hydrofluoroalkane propellant.

### **BACKGROUND OF THE INVENTION**

The delivery of drugs in pressurized metered-dose inhalers (MDI) currently employs the chlorofluorocarbons as propellants. As a result of the phase out of chlorofluorocarbons (potential depletion of the ozone layer), products marketed using chlorofluorocarbons must be reformulated using hydrofluoroalkane (HFA) propellants e.g 1,1,1,2-tetrafluoroethane (HFA 134a) and 1,1,1,2,3,3,3-heptafluoropropane (HFA 227), marketed by Du Pont Chemicals, Wilmington, Delaware, USA. The solvent behavior of the proposed alternative propellants is quite different from that of the chlorofluorocarbons. Difference in the physicochemical properties, such as polarity, vapor pressure and density, has posed challenges to the development of drug products in pressurized metered-dose inhalers for pulmonary delivery using hydrofluoroalkanes as propellants [Byron et al., Resp. Drug Deliv., 4 (1994)].

Numerous patent documents address these differences in physiochemical properties in formulations for inhalation. U.S. patent 5,492,688 relates to MDI formulations which utilize greater than 90% by weight of HFA 134a as the sole propellant, less than 5% w/w of micronized drug particles and less than 5% w/w of a polar surfactant selected from the group consisting of polyethylene glycol 300, diethylene glycol monoethyl ether, polyoxyethylene 20 sorbitan monooleate, propoxylated polyethylene glycol, and polyoxyethylene 4 lauryl ether.

World patent WO 91/04011 describes a self-propelling powder aerosol composition containing finely-divided, pre-micronized solid drug coated with a single non-perfluorinated surface-active dispersing agent suspended in an aerosol propellant in which the dispersing agent is substantially insoluble. Suitable

dispersing agents include various oils, sorbitan oleates, polyoxyethylene sorbitans, lecithins and polyoxyethylene among others. The quantity of surfactant used is kept to a minimum to avoid particle agglomeration and increase particle size.

World patent application 96/19197 relates to a pharmaceutical aerosol formulation comprising (a) a hydrofluoroalkane propellant; (b) a pharmaceutically active polypeptide dispersible in the propellant; and (c) a surfactant which is a C8-C16 fatty acid or salt thereof, a bile salt, a phospholipid, or an alkyl saccharide, which surfactant enhances the systemic absorption of the polypeptide in the lower respiratory tract. World patent application 96/19198 by the same inventors relates to a pharmaceutical aerosol formulation comprising a HFA propellant; a physiologically effective amount of a medicament for inhalation; and a surfactant which is a C8-C16 fatty acid or salt thereof, a bile salt, a phospholipid, or an alkyl saccharide. Both patents describe physical mixtures of active and surfactant in the propellant, with no prior encapsulation steps involved.

World patent application 96/40089 relates to a pharmaceutical aerosol formulation a pharmaceutical composition for aerosol delivery containing a medicament, a halogenated alkane propellant, and a biocompatible C16+-unsaturated vegetable oil.

World patent application 90/11754 relates to an aerosol formulation containing, as active ingredient, an azole antifungal in a form suitable for administration by inhalation.

World patent application 94/21228 relates to a medicinal aerosol formulation having a diol/diacid condensate as a dispersing agent, a propellant, and a therapeutically effective amount of a particulate drug.

World patent application 96/06598 relates to a pharmaceutical composition for aerosol delivery comprising a medicament, a non-chlorofluorocarbon propellant, and a polyglycolized glyceride.

World patent application 92/06675 relates to an aerosol formulation containing a therapeutically effective amount of beclomethasone 17,21 dipropionate, hydrofluorocarbon 1,1,1,2-tetrafluoroethane (HFA 134a) or 1,1,1,2,3,3,3-heptafluoropropane (HFA 227) propellant or a mixture and ethanol in an amount effective to solubilize the beclomethasone 17,21 dipropionate in the propellant. Substantially all the beclomethasone 17,21 dipropionate is dissolved in the formulation, and it is substantially free of any surfactant.

World patent application 93/05765 relates to a pressurized aerosol composition comprising a liquefied hydrofluoroalkane, a powdered medicament dispersible therein and a polymer soluble in the liquefied hydrofluoroalkane. The polymer includes, amide containing units or carboxylic acid ester containing units as recurring structural units.

U.S. patent 4,174,295 relates to a propellant composition for use with aerosols, the composition consisting essentially of a mixture of from 5 to 60% by weight, based on the total weight of the propellant composition, of a hydrogen-containing fluorocarbon selected from  $\text{CH}_2\text{F}_2$  and  $\text{CF}_3\text{-CH}_3$ , and from 40 to 95% by weight, based on the total weight of the propellant composition, of a hydrogen-containing chlorofluorocarbon or a hydrogen-containing fluorocarbon, each selected from  $\text{CF}_3\text{-CHClF}$ ,  $\text{CF}_3\text{-CH}_2\text{Cl}$ ,  $\text{CF}_3\text{-CH}_2\text{F}$ ,  $\text{CClF}_2\text{-CF}_3$  or  $\text{CHF}_2\text{-CH}_3$ .

U.S. patent 5,118,494 relates to a suspension aerosol formulation, including: a propellant comprising a hydrofluorocarbon selected from 1,1,1,2-tetrafluoroethane (HFA134a) or 1,1,1,2,3,3,3-heptafluoropropane (HFA227), or a mixture, a therapeutically effective amount of a powdered medicament; and

between about 0.001 and 0.6% by weight based on the total weight of the formulation of a perfluorinated carboxylic acid or ester as surface-active dispersing agent. The formulation exhibits substantially no crystallization of medicament over a prolonged period, is readily redispersible, and upon redispersion non flocculating so quickly as to prevent reproducible dosing of the medicament.

U.S. patent 5,126,123 relates to an aerosol inhalation drug formulation consisting essentially of a physiologically effective amount of a micronized inhalation drug and a 1,1,1,2-tetrafluoroethane-soluble, perfluorinated surfactant in suspension in 1,1,1,2-tetrafluoroethane.

U.S. patent 5,182,097 relates to an aerosol formulation for use in delivering medication to a patient via an inhalation device, comprising a propellant consisting solely of 1,1,1,2-tetrafluoroethane. The propellant represents at least 90% by weight of the aerosol formulation; an inhalable medicament dispersed or dissolved in a propellant, an inhalable medicant having a partition size less than 100 microns in diameter. The inhalable medicant represents no more than 5% by weight of aerosol formulation. Oleic acid employed as a surfactant for aiding in dispersing the inhalable medicant in the propellant, with oleic acid no more than 0.2% w/v of aerosol formulation.

U.S. patent 5,202,110 relates to an aerosol formulation for use in a metered dose inhaler, comprising a pharmaceutically acceptable inhalable propellant; a clathrate or molecular association of beclomethasone dipropionate employed as inhalable medicant dispersed or dissolved in a propellant. The clathrate or molecular association of beclomethasone dipropionate is formed with 1,1-dichloro-2,2,2-trifluoroethane, or 1,1-dichloro-1-fluoroethane, or dimethyl ether; the clathrate or molecular association having a particle size permitting inhalation.

U.S. patent 5,474,759 relates to an aerosol formulation consisting essentially of an effective amount of medicament; 1,1,1,2,3,3,3-heptafluoropropane (HFA 227); optionally, an excipient selected from a propylene glycol diester of a medium chain fatty acid or a triglyceride ester of a medium chain fatty acid. A surfactant is optionally present together with other excipients.

World patent application 96/32150 relates to a metered dose having part or all of its internal surfaces coated with one or more fluorocarbon polymers, optionally in combination with one or more non-fluorocarbon polymers, for dispensing an inhalation drug formulation of salmeterol, or a physiologically acceptable salt thereof, and a fluorocarbon propellant, optionally in combination with one or more other pharmacologically active agents or one or more excipients.

World patent application 96/32151 relates to a metered dose inhaler having part or all of its internal surfaces coated with one or more fluorocarbon polymers, optionally in combination with one or more non-fluorocarbon polymers, for dispensing an inhalation drug formulation of fluticasone propionate, or a physiologically acceptable solvate thereof, and a fluorocarbon propellant, optionally in combination with one or more other pharmacologically active agents or one or more excipients.

World patent application 96/18384 relates to a pharmaceutical aerosol formulation of 1,1,1,2-tetrafluoroethane (HFA 134a), 1,1,1,2,3,3,3-heptafluoropropane (HFA 227) or mixtures thereof as propellant; 1,1,2,2,3-pentafluoropropane as co-propellant; and particulate medicament.

World patent application 94/03153 relates to a pharmaceutical aerosol formulation of particulate beclomethasone dipropionate or an acceptable solvate

together with a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant.

World patent application 96/32099 relates to a metered dose inhaler having part or all of its internal surfaces coated with one or more fluorocarbon polymers, optionally in combination with one or more non-fluorocarbon polymers, for dispensing an inhalation drug formulation of albuterol, or a physiologically acceptable salt thereof, and a fluorocarbon propellant, optionally in combination with one or more other pharmacologically active agents or one or more excipients.

World patent application 93/11745 relates to a pharmaceutical aerosol formulation of a particulate medicament, a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant and up to 5% w/w based upon propellant of a polar cosolvent, which formulation is substantially free of surfactant.

World patent application 93/11743 relates to a pharmaceutical aerosol formulation comprising particulate medicament of salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate or their physiologically acceptable salts and solvates, and a fluorocarbon or hydrogen-containing chlorofluorocarbon. The formulation is substantially free of surfactant.

World patent application 93/15741 relates to a pharmaceutical aerosol formulation of beclomethasone dipropionate monohydrate, the particle size of substantially all the monohydrate being less than 20 microns; at least 0.015% w/w of the formulation of water in addition to the water of crystallization associated with the monohydrate; and a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant.

World patent application 93/11744 relates to pharmaceutical aerosol formulation of a particulate medicament and a fluorocarbon or hydrogen-



containing chlorofluorocarbon propellant, the formulation is substantially free of surfactant and when the medicament is other than salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate or physiologically acceptable salts or solvate thereof.

### **SUMMARY OF THE INVENTION**

In accordance with the present invention it has now surprisingly been found that particularly stable suspensions of microparticles in HFA 134a or HFA 227 are obtainable. These microparticles consist of drug microparticles coated with a phospholipid containing membrane. Preferably the drug particles are coated with a mixture of phospholipid(s) and at least one surfactant forming a membrane layer enveloping the outside of the microparticles. The mean particle size of the drug is reduced to between 100 nm to 10 microns, preferably 0.1 to 10 microns, by sonication or other processes inducing high shear and/or impaction in the presence of phospholipids or other membrane-forming amphiphatic lipids and, preferably, at least one surfactant. Dry powder is then obtained by drying the suspension. The dry powder of coated particles is conveniently suspended in the propellant. The membrane forming ingredients are used to obtain appropriate densities and polarities and decreased drug particle-coalescence, thus leading to well dispersible and stable drug suspensions in the hydrofluorocarbon propellants HFA 134a or HFA 227.

### **DESCRIPTION OF INVENTION**

In a preferred aspect of the invention drug particles are coated with mixtures of phospholipids and at least one surfactant with simultaneous size reduction to give a resultant mean particle size of 0.1 to 10 microns. These excipients are used in order to adjust the density, the polarity and the surface tension of the drug particles suspended in the propellant. Control of the density reduces the tendency of dispersed particles to either cream or sediment. The density of the formulation is preferred to be in the range of 1.0 to 1.5 g/ml so as to match with the density of the HFA propellants. Also, appropriate control of the

polarity and surface tension of the particles decrease drug-particle coalescence and to yields easily dispersible and stable drug suspensions.

In the membrane coating the weight ratio of phospholipid(s) to surfactant(s) is in the range of 0.01 to 100, preferably in the range of 0.02 to 50 and more preferably in the range of 0.04 to 25. The type and amount of surfactant and cosurfactant used is based on the relative solubility and/or polarity of these ingredients. The formulation compositions are hence optimized with respect to each drug individually. The encapsulation process minimizes the amounts of excipients needed to obtain acceptable formulations.

Importantly, the total amount of surface active agents, including phospholipids, is preferably more than 0.1% and less than 200% of the drug content.

### **DETAILED DESCRIPTION OF THE INVENTION**

#### **Methods of preparation**

**Sonication method:** The sonication process reduces the size of supra-molecular drug and phospholipid structures by the process of cavitation. The process creates small empty volumes that collapse, propelling material together at high speed, resulting in shattering and sheer. This allows one to simultaneously break up the ingredients into submicron fragments and coat the hydrophobic surface of microparticle. In the current invention the sonication process is used after the drug, the phospholipid(s), the surfactant(s) and any additional ingredient(s) are mixed together with a solvent. Sonication is performed at controlled temperature of between 5-10°C with sonic dismembrator model 550 (Fisher Scientific) fitted with 0.5 inch probe at a power setting of 3-5 for 5 to 60 min until the mean particle size reaches between 0.1-5 microns. In order to better control the temperature, sonication is performed with automated 10 seconds on and 10 seconds off cycle.

The product is then converted into dry form by lyophilization or spray drying to yield a powder which is then suspended in HFA 134a or HFA 227.

**Methods involving high pressure causing high shear and impaction:**

The drug together with other appropriate ingredients are homogenized by high pressure homogenization and/or microfluidization as known in the art. In the microfluidization process, high shear is created by collision of opposing microjets of liquids and impaction occurs between particle and at walls of the fluidizer. In the high pressure homogenization process, the sample is forced at high pressure and high shear through a narrow orifice and undergoes impaction against a wall and rapid decompression to atmospheric pressure. The product is then converted into dry form by lyophilization or spray drying to yield a powder which is then suspended in HFA 134a or HFA 227. Sonication and high shear and impaction methods are not limited to aqueous media but also may be performed in volatile organic solvents.

**Size reduction in air:** Drug crystals can also be reduced in size by high speed impact in air and then subsequently coated by phospholipid and surfactants. The product is then converted into dry form by lyophilization or spray drying to yield a powder which is then suspended in HFA 134a or HFA 227.

**Size reduction by in-flight crystallization:** A solution of the phospholipid(s), surfactant(s), the drug and any additional ingredient in a volatile solvent can be sprayed, with simultaneous removal of solvent by evaporation while in flight. The dried particles are collected on a smooth surface and suspended in one of the propellants.

**Size reduction by controlled crystallization methods:** such as crystallization using supercritical fluids.

Compositions of the current invention will include, in addition to the active, at least one phospholipid and optionally at least one surfactant.

Examples of suitable phospholipids are: diacylphosphatidylcholine in saturated or unsaturated form; diacylphosphatidylglycerols, diacylphosphatidylethanolamines, diacylphosphatidylinositols and diacylphosphatidylserines in saturated or unsaturated form and the corresponding lysophospholipids.

Examples of suitable surfactants are:

1. Polyoxyethylene-sorbitan-fatty acid esters; e.g. mono- and tri-lauryl, palmityl, stearyl and oleyl esters; e.g. products of the type known as polysorbates and commercially available under the trade name "Tween".
2. Polyoxyethylene fatty acid esters, e.g., polyoxyethylene stearic acid esters of the type known and commercially available under the trade name Myrj, such as Myrj 52.
3. Polyoxethylene castor oil derivatives, e.g., products of the type known and commercially available as Cremophors. Particularly suitable are polyoxyl 35 castor oil (Cremophor EL) and polyoxyl 40 hydrogenated castor oil (Cremophor RH40).
4. Vitamin E or its derivatives, such as D- $\alpha$ -tocopheryl polyethylene glycol 1000 succinate (vitamin E TPGS).
5. PEG glyceryl fatty acid esters such as PEG-8 glyceryl caprylate/caprate (commercially known as Labrasol), PEG-4 glyceryl caprylate/caprate (Labrafac Hydro WL 1219), PEG-32 glyceryl laurate (Gelucire 44/14), ), PEG-6 glyceryl mono oleate (Labrafil M 1944 CS), PEG-6 glyceryl linoleate (Labrafil M 2125 CS),

6. Propylene glycol mono- and di-fatty acid esters, such as propylene glycol laurate, propylene glycol caprylate/ caprate; also diethylene glycol monoethyl ether, commercially known as transcutol.
7. Sorbitan fatty acid esters, such as the type known and commercially available under the trade name Span (e.g., Span 20).
8. Polyoxyethylene-polyoxypropylene co-polymers, e.g., products of the type known and commercially available as Pluronic or Poloxamer, such as Poloxamer 188 NF.
9. Glycerol triacetate
10. Monoglycerides and acetylated monoglycerides, e.g., glycerol monooleate, glycerol monostearate and mono-and di- acetylated monoglycerides.
11. Bile salts
12. Polyethylene glycol (PEG); e.g. PEG 300, PEG 400, PEG 600, PEG 1000, PEG 1500, PEG 3400; such as the type known and commercially available under the trade name Carbowax, Lutrol E and Hodag PEG.
13. Substituted cellulose products such as hydroxypropylmethylcellulose, sodium carboxymethyl cellulose and hydroxypropylcellulose.
14. Carbomers, such as the type known and commercially available under the trade name Carbopol.

Suitable phospholipids and surfactants are not limited to those mentioned above, but may include any compound that would enhance the galenic properties of the formulations.

Compositions in accordance with the present invention may include other ingredients in addition to the drug, the phospholipid(s) and the surfactant(s). For example, the composition may include, in addition to the forgoing, one or more ingredients, additives or diluents such as pharmaceutically acceptable or inorganic materials, cryoprotectants such as trehalose and mannitol, anti-oxidants and preserving agents.

The aerosol formulation of the present invention is useful for the local or systemic treatment of diseases and may be administered for example topically or via the upper and lower respiratory tract, including by nasal route.

The following are illustrative but non limiting examples of compositions in accordance with the present invention.

In the following examples, microparticle formulations (30 ml scale) were prepared by addition of the ingredients into the appropriate solvent followed by sonication. The solvent was then evaporated, using e.g. lyophilization.

Appropriate amounts of the dry powder were then weighed and placed into aerosol bottles followed by the addition about 40 ml of HFA 134a per bottle. Bottles were then shaken by hand for about 1 min., sonicated for 15-30 min in a water bath sonicator and/or on a shaker overnight.

Component	Wt %
Example 1	
Beclomethasone dipropionate	0.0657
DPPC <sup>1</sup>	0.0263
Myrj 52	0.0263
HFA 134a	99.882
Example 2	
Beclomethasone dipropionate	0.327
DPPC	0.177
DMPG <sup>2</sup>	0.0026
Poloxamer 188 NF	0.0654
HFA 134a	99.428
Example 3	
Beclomethasone dipropionate	0.0657
DPPC	0.0131
Poloxamer 188 NF	0.0066
PEG 300	0.0066
HFA 134a	99.908
Example 4	
Flunisolide	0.3274
DPPC	0.0655
Poloxamer 188 NF	0.0524
PEG 1000	0.0131
HFA 134a	99.542

---

<sup>1</sup> 1,2-Dipalmitoyl-phosphatidylcholine<sup>2</sup> 1,2-Dimyristoyl-phosphatidylglycerol

## Example 5

Triamcinolone acetonide	0.2622
DPPC	0.0524
Poloxamer 188 NF	0.0420
PEG 1000	0.0105
HFA 134a	99.633

## Example 6

Salbutamol	0.1313
DPPC	0.0368
Myrj 52	0.0263
HFA 134a	99.806



**WHAT IS CLAIMED IS:**

1. An aerosol formulation consisting essentially of stabilized particles of drug microparticles in a size range of 0.1 to 10 microns coated with a membrane-forming amphipathic lipid and dispersed in 1,1,1,2-tetrafluoroethane (HFA 134a) or 1,1,1,2,3,3,3-heptafluoropropane (HFA 227) propellant.
2. The aerosol formulation of claim 1 in which the amphipathic lipid is a phospholipid.
3. The aerosol formulation of claim 2 in which the phospholipid coating also includes at least one surfactant.
4. An aerosol formulation consisting essentially of drug microcrystals in a mean size range of 0.1 to 10 microns coated with one or more membrane-forming phospholipids and at least one surfactant and dispersed in HFA 134a or HFA 227 propellant, wherein the density of the coated drug microparticles is substantially the same as the density of the propellant and the amount of coating on the drug microparticles is more than 0.1% and less than 200% of the weight of the drug.
5. The aerosol formulation of claim 1 or 4 in which the propellant represents at least 70% by weight of the formulation.
6. The aerosol formulation of claim 5 in which the propellant represents at least 90% by weight of the formulation.
7. The aerosol formulation of claim 5 in which the drug represents less than 5% by weight of the formulation.

8. The aerosol formulation of claim 3 or claim 4 in which the weight ratio of phospholipid to surfactant is in the range of 0.04 to 25.

9. The aerosol formulation of claim 3 or claim 4 in which the weight ratio of phospholipid to surfactant is in the range of 0.02 to 50.

10. The ratio of phospholipids to surfactants is in the range of 0.01 to 100; preferably in the range of 0.02 to 50; more preferably in the range of 0.04 to 25.

11. The aerosol formulation of claim 2 or 4 in which the phospholipid represents less than 20% by weight of the formulation.

12. The aerosol formulation of claim 2 in which the phospholipid represents less than 5% by weight of the formulation.

13. The aerosol formulation of claim 3 in which the surfactant represents less than 20% by weight of the formulation

14. The aerosol formulation of claim 3 or 4 in which the surfactant represents less than 5% by weight of the formulation.

15. A metered-dose inhaler containing an aerosol formulation of drug microparticles with a mean size from 0.1 to 10 microns suspended in a non-aqueous propellant selected from HFA134a, HFA227 or mixtures thereof, said drug microparticles coated and stabilized against coalescence with a membrane-forming amphiphatic lipid and optionally also a surfactant.

16. The inhaler of claim 15 in which the drug microparticles are coated with a phospholipid.

17. The inhaler of claim 15 or claim 16 in which the phospholipid coating also includes a surfactant.

18. A metered dose inhaler containing an aerosol formulation consisting essentially of drug microparticles in a mean size range of 0.1 to 10 microns coated with a mixture of phospholipids and at least one surfactant and dispersed in HFA 134a or HFA 227 propellant, wherein the density of the coated drug microcrystals is substantially the same as the density of the propellant and the amount of coating on the drug microparticles is no more than 0.1% and less than 200% of the weight of the drug.

19. Drug microparticles in a size range of 0.1 to 10 microns coated with a membrane-forming amphipathic lipid and optionally a surfactant and dispersed in a pharmaceutically acceptable carrier for delivery to the upper or lower respiratory tract.

20. Dry power consisting essentially of drug microparticles in a size range of 0.1 to 10 microns coated with a membrane-forming amphipathic lipid and optionally a surfactant for delivery to the upper or lower respiratory tract.

# INTERNATIONAL SEARCH REPORT

Inter. onal Application No

PCT/US 98/27922

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K9/00 A61K9/14 A61K9/50 A61K9/51 A61K47/24  
A61K47/06

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,Y	WO 91 04011 A (RIKER LABORATORIES INC) 4 April 1991	1,2,4-9, 11,12, 15-20 3
Y	see the whole document ---	
X,Y	EP 0 634 166 A (HOECHST AG) 18 January 1995	1,2,4-9, 11,12, 15-20 3
Y	see the whole document ---	
X,Y	WO 97 44012 A (ANDARIS LTD) 27 November 1997	1,2,4-9, 11,12, 15-20 3
Y	see the whole document ---	
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

16 April 1999

Date of mailing of the international search report

23/04/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Fischer, W

# INTERNATIONAL SEARCH REPORT

Inter. .onal Application No

PCT/US 98/27922

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,Y	WO 93 15741 A (GLAXO GROUP LTD) 19 August 1993	1,2,4-9, 11,12, 15-20
Y	see the whole document ---	3
X,Y	WO 96 18384 A (GLAXO GROUP LTD ;SAPSFORD ANDREW (GB); SAVAGE ANDREW PATRICK (GB)) 20 June 1996 cited in the application	1,2,4-9, 11,12, 15-20
Y	see the whole document ---	3
X,Y	WO 96 19197 A (ASTRA AB ;BAECKSTROEM KJELL (SE); DAHLBAECK MAGNUS (SE); JOHANSSON) 27 June 1996	1,2,4-9, 11,12, 15-20
Y	see the whole document ---	3
X,Y	WO 96 19198 A (ASTRA AB ;BAECKSTROEM KJELL (SE); DAHLBAECK MAGNUS (SE); JOHANSSON) 27 June 1996	1,2,4-9, 11,12, 15-20
Y	see the whole document ---	3
A	WO 91 11495 A (BOEHRINGER INGELHEIM INT ;BOEHRINGER INGELHEIM KG (DE)) 8 August 1991	
A	US 5 492 688 A (BYRON PETER R ET AL) 20 February 1996 cited in the application ---	
A	EP 0 535 567 A (BRAUN MELSUNGEN AG) 7 April 1993 -----	

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Inter. .onal Application No

PCT/US 98/27922

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9104011 A	04-04-1991	AU 648994 B AU 6409790 A DE 69021387 D DE 69021387 T EP 0493437 A JP 5500664 T US 5348730 A	12-05-1994 18-04-1991 07-09-1995 25-01-1996 08-07-1992 12-02-1993 20-09-1994
EP 0634166 A	18-01-1995	DE 4323636 A CA 2128034 A JP 7053353 A US 5663198 A	19-01-1995 16-01-1995 28-02-1995 02-09-1997
WO 9744012 A	27-11-1997	AU 2783897 A	09-12-1997
WO 9315741 A	19-08-1993	AP 419 A AT 157875 T AU 667074 B AU 3452593 A BG 61862 B BG 98897 A CA 2128688 A CN 1078633 A CZ 9401846 A DE 69313825 D DE 69313825 T DK 625046 T EP 0625046 A ES 2106360 T GR 3025363 T HU 68986 A HU 9500177 A IL 104628 A JP 7503476 T MX 9300620 A NO 942923 A NZ 246889 A SK 92494 A US 5695744 A US 5688782 A ZA 9300800 A	24-10-1995 15-09-1997 07-03-1996 03-09-1993 31-08-1998 28-02-1995 19-08-1993 24-11-1993 15-03-1995 16-10-1997 05-02-1998 27-04-1998 23-11-1994 01-11-1997 27-02-1998 28-08-1995 28-08-1995 27-12-1998 13-04-1995 01-08-1993 05-08-1994 26-11-1996 12-04-1995 09-12-1997 18-11-1997 06-10-1993
WO 9618384 A	20-06-1996	AU 4260496 A EP 0789557 A JP 10510521 T	03-07-1996 20-08-1997 13-10-1998
WO 9619197 A	27-06-1996	AU 702879 B AU 4359196 A BR 9510501 A CA 2206736 A CN 1171046 A CZ 9701945 A EP 0797431 A FI 972657 A HU 77701 A JP 10510827 T NO 972781 A PL 320824 A	11-03-1999 10-07-1996 13-01-1998 27-06-1996 21-01-1998 15-10-1997 01-10-1997 19-06-1997 28-07-1998 20-10-1998 16-06-1997 10-11-1997

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/27922

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9619197 A		SK 81397 A	05-11-1997
		ZA 9510752 A	24-06-1996
WO 9619198 A	27-06-1996	AU 702880 B	11-03-1999
		AU 4359396 A	10-07-1996
		BR 9510510 A	07-07-1998
		CA 2206782 A	27-06-1996
		CN 1170356 A	14-01-1998
		CZ 9701947 A	15-10-1997
		EP 0806940 A	19-11-1997
		FI 972655 A	19-06-1997
		HU 77775 A	28-08-1998
		JP 10510829 T	20-10-1998
		NO 972681 A	11-06-1997
		PL 320856 A	10-11-1997
		SK 81197 A	05-11-1997
		ZA 9510754 A	24-06-1996
WO 9111495 A	08-08-1991	DE 4003272 A	08-08-1991
		AT 165863 T	15-05-1998
		AU 650001 B	09-06-1994
		AU 7211391 A	21-08-1991
		CA 2075058 A	04-08-1991
		CS 9100264 A	15-09-1991
		DE 59108979 D	10-06-1998
		EP 0514415 A	25-11-1992
		ES 2117964 T	01-09-1998
		FI 923490 A	03-08-1992
		HR 940735 A	30-06-1997
		IL 97028 A	26-08-1994
		JP 5504160 T	01-07-1993
		NO 302419 B	02-03-1998
		PT 96634 A,B	31-10-1991
		SI 9110156 A	30-04-1998
US 5492688 A	20-02-1996	NONE	
EP 0535567 A	07-04-1993	DE 4132677 A	08-04-1993
		DE 59203456 D	05-10-1995
		ES 2077317 T	16-11-1995